Inflammatory breast cancer
Inflammatory breast cancer develops when cancer cells block the lymph vessels in the skin of the breast. It is called inflammatory because the breast becomes red and swollen.
Inflammatory breast cancer develops more often in younger women and women of African ancestry.
Inflammatory breast cancer is rare and aggressive, which means that it grows and spreads quickly. In most cases, inflammatory breast cancer has already spread to the lymph nodes or other organs when it is diagnosed.
Inflammatory breast cancer starts to cause symptoms soon after it develops. Many of the symptoms appear at the same time.
The most common symptom of inflammatory breast cancer is a change to the colour of the skin on at least one-third of the breast. The skin becomes very red or purplish in colour.
Other symptoms of inflammatory breast cancer include:
- a swollen breast
- dimpled or pitted skin that looks like an orange peel (called peau d’orange)
- thickened skin or breast tissue
- a breast that feels warm to the touch
- an increase in the size of the breast
- changes to the nipple such as a nipple that suddenly starts to point inward (called an inverted nipple)
- tenderness or pain in the breast
- itching or burning
- a lump in the armpit (called the axilla), or near the collarbone
The symptoms of inflammatory breast cancer are very similar to the symptoms of infection in the breast tissue (called mastitis), which is more common in breastfeeding women. Doctors may prescribe antibiotics to treat mastitis, but waiting for the antibiotics to work may delay the diagnosis of inflammatory breast cancer. As a result, it is often diagnosed at an advanced stage. Inflammatory breast cancer is considered stage 3B breast cancer, or locally advanced breast cancer, which means that it has started to grow into surrounding tissues.
Inflammatory breast cancer can be difficult to diagnose. This is because this type of cancer doesn’t usually cause a lump in the breast that can be felt by the doctor, or seen with mammography. An important part of diagnosing inflammatory breast cancer are the signs and symptoms, and how quickly they start.
The following tests are usually used to diagnose breast cancer, including inflammatory breast cancer. Many of the same tests used to diagnose cancer are used to find out the stage (how far the cancer has progressed). Your doctor may also order other tests to check your general health and to help plan your treatment.
- physical exam
- clinical breast exam
- diagnostic mammography
- hormone receptor status testing
- HER2 status testing
Find out more about diagnosis of breast cancer.
If you have inflammatory breast cancer, your healthcare team will create a treatment plan just for you. It will be based on your health and specific information about the cancer.
Chemotherapy is the first treatment given for inflammatory breast cancer. It is used to destroy cancer cells in the breast and anywhere else they may be in the body. It is given before surgery (called neoadjuvant therapy). It is also given for a period of time after surgery (called adjuvant therapy).
Chemotherapy for inflammatory breast cancer is usually given as a combination of drugs because research shows that this is more effective than single drugs on their own. The types of chemotherapy used include an anthracycline and a taxane drug. These drugs are given one after another because giving them at the same time can increase the risk for heart problems.
The following combinations of chemotherapy drugs may be used:
- CEF – cyclophosphamide (Cytoxan, Procytox), epirubicin (Pharmorubicin) and 5-fluorouracil (Adrucil, 5-FU)
- AC > Taxol – doxorubicin (Adriamycin) and cyclophosphamide, followed by paclitaxel (Taxol)
- Taxol > FAC – paclitaxel followed by cyclophosphamide, doxorubicin and 5-fluorouracil
After several rounds of chemotherapy, you will have a mammography to find out how well the treatment is working. If the first combination of chemotherapy drugs doesn’t work, you may be given other combinations of drugs.
Find out more about chemotherapy for breast cancer.
Trastuzumab (Herceptin) is a type of targeted therapy. It is given with chemotherapy if the cancer is HER2 positive. Up to 60% of inflammatory breast cancers are HER2 positive.
Surgery is offered if chemotherapy shrinks the tumour. The following types of surgery are used for inflammatory breast cancer.
Modified radical mastectomy is used to treat inflammatory breast cancer that has not spread to other parts of the body. Doctors need to remove all of the breast because there is a high risk that this cancer will come back (recur). This is why breast-conserving surgery is not offered for inflammatory breast cancer.
Axillary lymph node dissection is used to remove lymph nodes under the arm (called the axilla). This surgery is done because inflammatory breast cancer has often already spread to these lymph nodes when it is diagnosed.
Find out more about surgery for breast cancer.
Radiation therapy is usually given after surgery for inflammatory breast cancer. It is used to lower the risk that the cancer will come back in the area where the breast was removed. External beam radiation therapy is directed at muscles on the chest and lymph nodes in the chest, shoulder and underarm.
Find out more about radiation therapy for breast cancer.
Hormonal therapy may be offered to women who have inflammatory breast cancer that has certain hormone receptors (called a hormone receptor–positive tumour). The type of hormonal therapy offered will depend on whether or not you have reached menopause.
Tamoxifen (Nolvadex, Tamofen) is offered to women who have not yet reached menopause (they are premenopausal).
Anastrozole (Arimidex) and letrozole (Femara) are aromatase inhibitors. Post-menopausal women (those who have gone through menopause) will be offered one of these drugs.
Find out more about hormonal therapy for breast cancer.
Prognosis and survival
If you have inflammatory breast cancer, you may have questions about your prognosis. A prognosis is the doctor’s best estimate of how cancer will affect someone and how it will respond to treatment. Prognosis and survival depend on many factors. Only a doctor familiar with your medical history, the type, stage and characteristics of your cancer, the treatments chosen and the response to treatment can put all of this information together with survival statistics to arrive at a prognosis.
Inflammatory breast cancer has a lower survival rate than other types of breast cancer. According to US statistics for 1988–2001, the 5-year relative survival for women with inflammatory breast cancer is 34%. This means that, on average, women diagnosed with inflammatory breast cancer are 34% as likely to live 5 years after their diagnosis as people in the general population.
If you have inflammatory breast cancer, talk to your healthcare team about your prognosis.
A tube through which lymph fluid travels in the body.
A protein on or in a cell that binds with a specific hormone, which can cause different changes to take place in the cell.
For certain types of cancer, a lab test will be used to find out if cancer cells have specific hormone receptors (referred to as hormone receptor status). Cancer cells that have the receptors are referred to as receptor positive (+). Cancer cells that don’t have the receptors are referred to as receptor negative (–).
The time in a woman’s life when her ovaries stop producing estrogen and she has not had a menstrual period for 12 months. Most women start menopause between 45 and 55 years of age.
Menopausal means referring to or having to do with menopause, as in menopausal symptoms.
Sometimes referred to as change of life.
See also premenopause, perimenopause and post-menopause.
A drug that stops the production or blocks the actions of the enzyme aromatase, which in turn lowers the level of estradiol (a female hormone) in the body.
Aromatase inhibitors are a type of anti-estrogen therapy.
Funding world-class research
Cancer affects all Canadians but together we can reduce the burden by investing in research and prevention efforts. Learn about the impact of our funded research.